Alteogen challenges to KRW 2 trillion hemophilia biomedicine ‘NovoSeven’
Alteogen Inc.(CEO Soon-Jae Park) held an agreement ceremony on the 29th of November as its long-acting hemophilia treatment being developed, ‘ALT-Q2,’ was selected as a project to develop a substance candidate for a preclinical trial from the Korea Drug Development Fund(CEO Sang-Aun Joo).
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.